Innoviva, Inc. — Director's Dealing 2021

May 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entasis Therapeutics Holdings Inc. (ETTX)
CIK: 0001724344
Period of Report: 2021-05-03

Reporting Person: Innoviva, Inc. (10% Owner)
Reporting Person: Innoviva Strategic Opportunities LLC (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-03	Common Stock	P	3731025	$2	Acquired	3731025	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-03	Warrants to Purchase Common Stock	$2.00	P	3731025	Acquired	2026-05-03	Common Stock (3731025)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18672897	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants to Purchase Common Stock	$		Common Stock (18672897)	18672897	Direct

Footnotes

F1: As reflected in the Amendment No. 4 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on May 3, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on May 3, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 3,731,025 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 3,731,025 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4.

F2: INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020.